<zvk class="wikcl"></zvk>

南宫NG28基因

Be the most trusted biotech company

2025-05-21

Henlius Strengthens Information Security with ISO/IEC 27001:2022 Certification Upgrade
2025-05-16

First Subject Dosed for Phase 1/3 Clinical Trial of Henlius’ Proposed Ipilimumab Biosimilar
2025-05-14

Henlius Included in MSCI Global Small Cap Indexes, Reinforcing Its Position in Global Capital Markets
2025-05-13

Henlius Will Be at BIO 2025
2025-05-08

Latest Results of Serplulimab in Gastric Cancer Released at IGCC 2025
2025-04-29

Henlius Enters into License Agreement with Sandoz for Proposed Ipilimumab Biosimilar
2025-04-28

Henlius Receives Clinical Approval in EU for Head-to-Head Phase 3 MRCT of Dual HER2 Blockade Therapy on First-Line HER2+ GC
2025-04-28

Preclinical Results of Henlius’ Multiple Innovative Candidates Debut at AACR 2025
2025-04-25

Henlius Enters Exclusive License Agreement with Lotus for Anti-PD-1 mAb Serplulimab in South Korea